SFRP5 and morbid obesity: Furthermore, the increase in Sfrp5 concentrations in patients with morbid obesity was accompanied by improvement in clinical parameters (decreased BMI, BMI z-score, DBP, WHR, WHtR, and percentage of fat percentage; increased muscle mass and fat-free mass), hepatic enzymes (decreased ALT, γ-GT), lipid profile (decreased TG, ApoB; increased HDL concentrations), and insulin-sensitivity indices (HbA1C, HOMA index).